BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee R, Kottilil S, Wilson E. Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy. Hepatol Int 2017;11:161-70. [PMID: 27928718 DOI: 10.1007/s12072-016-9776-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Kazmierski WM, Miriyala N, Johnson DK, Baskaran S. The Discovery of Conformationally Constrained Bicyclic Peptidomimetics as Potent Hepatitis C NS5A Inhibitors. ACS Med Chem Lett 2021;12:1649-55. [PMID: 34790290 DOI: 10.1021/acsmedchemlett.1c00391] [Reference Citation Analysis]
2 Zignego AL, Monti M, Gragnani L. Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection. Acta Biomed 2018;89:321-31. [PMID: 30333452 DOI: 10.23750/abm.v89i3.7718] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Sedeño-Monge V, Laguna-Meraz S, Santos-López G, Panduro A, Sosa-Jurado F, Jose-Abrego A, Meléndez-Mena D, Muñoz-Ramírez MA, Cosme-Chávez M, Roman S. A comprehensive update of the status of hepatitis C virus (HCV) infection in Mexico-A systematic review and meta-analysis (2008-2019). Ann Hepatol 2021;20:100292. [PMID: 33259949 DOI: 10.1016/j.aohep.2020.100292] [Reference Citation Analysis]
4 Chugh Y, Premkumar M, Grover GS, Dhiman RK, Teerawattananon Y, Prinja S. Cost-effectiveness and budget impact analysis of facility-based screening and treatment of hepatitis C in Punjab state of India. BMJ Open 2021;11:e042280. [PMID: 33589457 DOI: 10.1136/bmjopen-2020-042280] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Abutaleb A, Kottilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. Hepatol Int 2018;12:214-22. [PMID: 29845496 DOI: 10.1007/s12072-018-9873-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
6 Yang YM, Choi EJ. Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials. Ther Clin Risk Manag 2017;13:477-97. [PMID: 28442915 DOI: 10.2147/TCRM.S134818] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Gottlieb RL, Hall SA. The New Direct Antiviral Agents and Hepatitis C in Thoracic Transplantation: Impact on Donors and Recipients. Curr Transplant Rep 2018;5:145-52. [PMID: 29774177 DOI: 10.1007/s40472-018-0192-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
8 Jin G, Lee J, Lee K. Chemical genetics-based development of small molecules targeting hepatitis C virus. Arch Pharm Res 2017;40:1021-36. [PMID: 28856597 DOI: 10.1007/s12272-017-0949-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Huang YT, Hsieh YY, Chen WM, Tung SY, Wei KL, Shen CH, Chang KC, Lu CK, Yen CW, Lu SN, Hung CH, Chang TS. Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan. BMC Gastroenterol 2021;21:259. [PMID: 34118889 DOI: 10.1186/s12876-021-01837-y] [Reference Citation Analysis]
10 Pan S, Feng K, Huang P, Zeng Y, Ke L, Yang X, Liu J, Lin C. Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China. Medicine (Baltimore) 2021;100:e26312. [PMID: 34128871 DOI: 10.1097/MD.0000000000026312] [Reference Citation Analysis]
11 Ray AK, Sen Gupta PS, Panda SK, Biswal S, Bhattacharya U, Rana MK. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery. Comput Biol Med 2021;142:105183. [PMID: 34986429 DOI: 10.1016/j.compbiomed.2021.105183] [Reference Citation Analysis]
12 Shiani A, Narayanan S, Pena L, Friedman M. The Role of Diagnosis and Treatment of Underlying Liver Disease for the Prognosis of Primary Liver Cancer. Cancer Control 2017;24:1073274817729240. [PMID: 28975833 DOI: 10.1177/1073274817729240] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
13 Gottlieb RL, Sam T, Wada SY, Trotter JF, Asrani SK, Lima B, Joseph SM, Gonzalez-Stawinski GV, Hall SA. Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse. J Card Fail 2017;23:765-7. [PMID: 28801074 DOI: 10.1016/j.cardfail.2017.08.448] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
14 Zhang Y, Chen LM, He M. Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution. Virol J. 2017;14:41. [PMID: 28231805 DOI: 10.1186/s12985-017-0710-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
15 Elkady EF, Aboelwafa AA. Rapid bioanalytical LC-MS/MS method for the simultaneous determination of sofosbuvir and velpatasvir in human plasma-application to a pharmacokinetic study in Egyptian volunteers. J Chromatogr B Analyt Technol Biomed Life Sci 2018;1102-1103:116-24. [PMID: 30384188 DOI: 10.1016/j.jchromb.2018.10.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
16 Li M, Zhuang H, Wei L. How would China achieve WHO's target of eliminating HCV by 2030? Expert Rev Anti Infect Ther 2019;17:763-73. [PMID: 31578079 DOI: 10.1080/14787210.2019.1675509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
17 Abdurakhmanov E, Øie Solbak S, Danielson UH. Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase. Viruses 2017;9:E151. [PMID: 28621755 DOI: 10.3390/v9060151] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
18 Chugh Y, Dhiman RK, Premkumar M, Prinja S, Singh Grover G, Bahuguna P. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India. PLoS One 2019;14:e0221769. [PMID: 31465503 DOI: 10.1371/journal.pone.0221769] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
19 Kazmierski WM, Baskaran S, Walker JT, Miriyala N, Meesala R, Beesu M, Adjabeng G, Grimes RM, Hamatake R, Leivers MR, Crosby R, Xia B, Remlinger K. GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage. J Med Chem 2020;63:4155-70. [PMID: 32202782 DOI: 10.1021/acs.jmedchem.9b02176] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]